Haydee is a preclinical medical device strategist with extensive experience in designing and orchestrating non-clinical safety and efficacy studies. Previously a Study Director at NAMSA, Haydee specialized in optimizing strategies to streamline the in vivo testing pathway, from early feasibility through Good Laboratory Practices (GLP) studies for regulatory submission. In this role, she managed a vast portfolio of non-clinical studies across complex device specialties, including coronary artery bypass grafts (CABG), transcatheter valve replacement (TAVR, TMVR), neurovascular thrombectomy, and targeted drug delivery, among many others. Since leaving NAMSA, Haydee has served as a preclinical consultant, supporting her clients in developing and implementing efficient, robust preclinical programs to maximize success in achieving regulatory clearance. Haydee holds a Bachelor’s Degree in Public Health and a Master’s Degree in Environmental Health Sciences/Developmental Toxicology from the University of Massachusetts (Amherst, MA).